[go: up one dir, main page]

WO2008067065A3 - Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers - Google Patents

Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers Download PDF

Info

Publication number
WO2008067065A3
WO2008067065A3 PCT/US2007/081792 US2007081792W WO2008067065A3 WO 2008067065 A3 WO2008067065 A3 WO 2008067065A3 US 2007081792 W US2007081792 W US 2007081792W WO 2008067065 A3 WO2008067065 A3 WO 2008067065A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
systems
methods
kits
diagnosing
Prior art date
Application number
PCT/US2007/081792
Other languages
French (fr)
Other versions
WO2008067065A2 (en
Inventor
Shiv Srivastava
Albert Dobi
Kee-Hong Kim
Gyorgy Petrovics
Original Assignee
Shiv Srivastava
Albert Dobi
Kee-Hong Kim
Gyorgy Petrovics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiv Srivastava, Albert Dobi, Kee-Hong Kim, Gyorgy Petrovics filed Critical Shiv Srivastava
Publication of WO2008067065A2 publication Critical patent/WO2008067065A2/en
Publication of WO2008067065A3 publication Critical patent/WO2008067065A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to secreted protein biomarkers for prostate cancer, diagnostic and prognostic kits comprising reagents that bind the secreted protein biomarkers, and methods and systems for using those biomarkers to diagnose and prognose prostate cancer.
PCT/US2007/081792 2006-10-19 2007-10-18 Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers WO2008067065A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85264006P 2006-10-19 2006-10-19
US60/852,640 2006-10-19

Publications (2)

Publication Number Publication Date
WO2008067065A2 WO2008067065A2 (en) 2008-06-05
WO2008067065A3 true WO2008067065A3 (en) 2009-03-12

Family

ID=39468577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081792 WO2008067065A2 (en) 2006-10-19 2007-10-18 Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers

Country Status (1)

Country Link
WO (1) WO2008067065A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138392A1 (en) * 2008-05-14 2009-11-19 ETH Zürich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
WO2010017102A2 (en) * 2008-08-06 2010-02-11 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methods for intracellular modulation of bone morphogenetic protein signaling
US20120190565A1 (en) * 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
WO2010096627A1 (en) * 2009-02-20 2010-08-26 Lisanti Michael P Therapeutics and methods for treating neoplastic diseases comprising determining the level of caveolin-1 and/or caveolin-2 in a stromal cell sample
WO2011064179A1 (en) * 2009-11-26 2011-06-03 F. Hoffmann-La Roche Ag Marker protein for type 2 diabetes
EP3112871B1 (en) 2009-12-20 2020-07-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120028264A1 (en) * 2010-07-27 2012-02-02 Steven Shak Method for using gene expression to determine prognosis of prostate cancer
AU2015227398B2 (en) * 2010-07-27 2017-08-31 Mdxhealth Sa Method for using gene expression to determine prognosis of prostate cancer
JP6196163B2 (en) 2011-03-17 2017-09-13 ミネルバ バイオテクノロジーズ コーポレーション Methods for producing pluripotent stem cells
US20140127708A1 (en) * 2011-05-10 2014-05-08 Nuclea Biotechnologies, Inc. Predictive biomarkers for prostate cancer
WO2013040358A2 (en) * 2011-09-14 2013-03-21 University Of Washington Through Its Center For Commercialization Assays and compositions for detection of agr2
JP6466170B2 (en) 2011-10-17 2019-02-06 ミネルバ バイオテクノロジーズ コーポレーション Medium for stem cell growth and induction
US8632971B2 (en) 2011-11-08 2014-01-21 Caldera Health Limited Methods and materials for determining the efficacy of prostate cancer therapies
US8658166B2 (en) 2011-11-08 2014-02-25 Caldera Health Limited Methods and materials for the diagnosis of prostate cancers
US20130116131A1 (en) 2011-11-08 2013-05-09 Caldera Health Limited Methods and materials for the diagnosis of prostate cancers
US8658164B2 (en) 2011-11-08 2014-02-25 Caldera Health Limited Methods and materials for the diagnosis of prostate cancers
EP2788759B1 (en) * 2011-12-08 2019-02-20 Astute Medical, Inc. Methods and uses for diagnosis of renal injury and renal failure
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
EP3179393B1 (en) 2012-01-31 2020-07-08 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
JP6546087B2 (en) * 2012-07-24 2019-07-17 ミネルバ バイオテクノロジーズ コーポレーション Expression and suppression of NME variant species
US10081842B2 (en) 2012-08-07 2018-09-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene expression profiles
ES2681955T3 (en) 2013-01-17 2018-09-17 Astute Medical, Inc. Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
JP5429725B1 (en) * 2013-03-22 2014-02-26 独立行政法人理化学研究所 Prostate cancer progression evaluation method, prostate cancer detection method, and test kit
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
CN103293320B (en) * 2013-05-22 2015-03-25 上海市第十人民医院 Application of cysteine-rich secretory protein 1 (CRISP 1) in preparation of gingival cancer diagnosis products
CN103267856B (en) * 2013-05-22 2015-04-29 上海市第十人民医院 Application of kit for diagnosing jaw cancer
CN103293296A (en) * 2013-05-22 2013-09-11 苏州市马尔泰新材料有限公司 Application of cysteine-rich secretory protein 1 (CRISP 1) in preparation of kit for diagnosing carcinoma of floor of mouth
CN103267858B (en) * 2013-05-22 2015-03-25 上海市第十人民医院 Application of CRISP1 (Cysteine-Rich Secretory Protein 1) in preparing gold label test paper for diagnosing salivary gland carcinoma
CN103267860B (en) * 2013-05-22 2015-04-29 上海市第十人民医院 Application of CRISP1 (Cysteine-Rich Secretory Protein 1) in preparing kit for diagnosing jawbone carcinoma
CN103257241B (en) * 2013-05-22 2015-04-29 上海市第十人民医院 New application of CRISP (cysteine-rich secretory protein)1 to medical instrument
CN103267862A (en) * 2013-05-22 2013-08-28 苏州市马尔泰新材料有限公司 Application of CRISP1 (Cysteine-Rich Secretory Protein 1) in preparing gold label kit for diagnosing maxillary sinus carcinoma
CN103278644A (en) * 2013-05-22 2013-09-04 苏州市马尔泰新材料有限公司 Gold-labelled CRISP (cysteine-rich secretory protein)1 kit for quickly diagnosing carcinoma of palate
CN110007084B (en) 2013-12-03 2022-11-18 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
WO2016127999A1 (en) * 2015-02-10 2016-08-18 University Of Copenhagen Neuropeptide y as a prognostic marker of prostate cancer
EP3281011B1 (en) 2015-04-09 2024-06-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10703786B2 (en) * 2015-10-30 2020-07-07 The University Of Melbourne Methods and compositions for improving glucose metabolism
ITUA20161418A1 (en) * 2016-03-07 2017-09-07 Univ Degli Studi Di Torino URINARY BIOMARCERS FOR DIAGNOSIS OF THE PROSTATE CARCINOMA
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN110257515B (en) * 2019-06-14 2023-03-31 清华-伯克利深圳学院筹备办公室 Molecular marker for breast cancer diagnosis and application thereof
WO2022011093A1 (en) * 2020-07-08 2022-01-13 Board Of Regents, The University Of Texas System Methods for the detection and treatment of prostate cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101357A2 (en) * 2001-06-10 2002-12-19 Irm Llc Molecular signatures of commonly fatal carcinomas
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2006053328A2 (en) * 2004-11-12 2006-05-18 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring prostate disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101357A2 (en) * 2001-06-10 2002-12-19 Irm Llc Molecular signatures of commonly fatal carcinomas
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2006053328A2 (en) * 2004-11-12 2006-05-18 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring prostate disease

Also Published As

Publication number Publication date
WO2008067065A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2008067065A3 (en) Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2007064776A3 (en) Markers for breast cancer
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
WO2007100919A3 (en) Markers for addiction
WO2007146385A3 (en) Albumin-bound protein/peptide complex as a biomarker for disease
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
EP1922326A4 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
IL180997A0 (en) Diagnostic methods and kits utilizing platelet biomarkers for cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2009036427A3 (en) Prostate cancer biomarkers
WO2008048970A3 (en) Synthetic antibodies
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2007047408A3 (en) Promac signature application
WO2012076553A3 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
DE602007011566D1 (en) Ankheit
GB0720113D0 (en) Diagnostic, prognostic and predictive testing for cancer
WO2008008500A3 (en) Methods for making cancer prognoses based on the subcellular localization of biomarkers
WO2009140039A3 (en) Synthetic antibodies
WO2010096674A3 (en) A+ biomarker assays
WO2006102526A3 (en) Identification of biomarkers by serum protein profiling
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
AU2007266218B2 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871183

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07871183

Country of ref document: EP

Kind code of ref document: A2